Nathan Fowler

CMO-BostonGene; Pres-Halo House Foundation; ex Prof of Med-MD Anderson. Constantly searching for innovative ways to battle cancer and improve patients lives

[Nathan Fowler @DrNathanFowler]

Please check out this most recent podcast, where I talk with MaryBeth Gilliam from Outperform Cancer about the importance of genetic testing and how AI is transforming cancer . https://t.co/Dz0wISGNpJ

[Latest News from Business Wire @NewsFromBW]

BostonGene to Present Seven Studies Unveiling Novel AI-Driven Breast Cancer Breakthroughs at SABCS 2025 https://t.co/7VnruhFqkY

[Nathan Fowler @DrNathanFowler]

Beating cancer requires more than just therapy. In the middle of a campaign to double the size of Halo House. Check out our recent campaign video!
https://t.co/xpMnviFg5t

[Nathan Fowler @DrNathanFowler]

RNA data in cancer is complex, tough to interpret, and often poorly understood. Today we published a new AI tool to help define "bad". AI is changing how we will use technology to better understand cancer. https://t.co/JK3vrg6ITS

[Nathan Fowler @DrNathanFowler]

thanks everyone for your support. https://t.co/UJ2TsjMXBz

[Bloodbytes @DrSwami_Iyer]

Excellente presentation by Ranjit Nair @MDAndersonNews @LNastoupilMD @ChrisRFlowersMD showcasing the very promising phase 1 study results of TNB-486 in R/R FL.

[Nathan Fowler @DrNathanFowler]

@DrSwami_Iyer @MDAndersonNews @LNastoupilMD @ChrisRFlowersMD @WomenInLymphoma @Lymphoma_Doc @lymphomahub @PallawiTorkaMD @majorajay @Eddie_Cliff @DrAnasYounes @doctorpemm Great job. Our rising star.

[Mark Lewis, MD, FASCO @marklewismd]

He’s got some truly incredible content but this might be my favorite @DGlaucomflecken tweet of all time

[Nature Medicine @NatureMedicine]

In an interim analysis of the pivotal phase 2 ELARA trial, anti-CD19 #CARTcells produced a high rate of complete responses with a manageable safety profile in adults with r/r #FollicularLymphoma #lymsm #immunotherapy @DrNathanFowler @NovartisCancer https://t.co/bGTHaeV85t

[Nathan Fowler @DrNathanFowler]

Very proud of you!!!!

[OncData Lyn @OncDataLyn]

The #FDA has given accelerated approval to #tisagenlecleucel for treatment of adult patients with relapsed or refractory #follicular #lymphoma (#FL). Read about the #ELARA trial, published in @NatureMedicine by @DrNathanFowler that led to the approval: https://t.co/1iuoqAldCx

[Nathan Fowler @DrNathanFowler]

@GuiperiniMD @MDAndersonNews @bpromd @lefayad @michaelwangmd You are awesome!

[Nathan Fowler @DrNathanFowler]

@MediHumdani If pt is in CR, I would agree with going to commercial CAR-T. Biopsy would be nice, but unclear if CD19 status should affect next steps..as Lonca could cause dynamic (and temporary) expression change. Happy to talk off line.

[PeerView @PeerView]

See what our experts Drs. Fowler (@DrNathanFowler), Nancy L. Bartlett, & Patel (@KrishPatelMD) have to say about targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of #FollicularLymphoma. #ASH21 https://t.co/FIAgkyMzWr #meded #lymsm

[Chan Cheah @chanyooncheah]

Congratulations @DrNathanFowler et al on these important data. Love to see a trial vs mosun

[Nathan Fowler @DrNathanFowler]

@AshAlizadeh So sorry to hear. He was a great person and colleague. Always kind and insightful.

[Nathan Fowler @DrNathanFowler]

Phenomenal. Congrats Dr Jabbour and team!

[Hagop Kantarjian,MD @DrHKantarjian]

A combination of 2 targeted drugs, ponatinib+ blinatumomab, WITHOUT ANY CHEMOTHERAPY,  results in 100% complete response rate, 85% complete molecular remission rate in newly diagnosed pts w/ Ph-positive #ALL. @MDAndersonNews study led by @NicholasShortMD & Jabbour #leusm #ASCO21

[Nathan Fowler @DrNathanFowler]

Very cool summary of our recent paper in Cancer Cell. Major impact!

[Cancer Cell @Cancer_Cell]

A tumor “personality” test to guide therapeutic decision making https://t.co/CMVNBXBNqw

[Nathan Fowler @DrNathanFowler]

@JohnPLeonardMD Agree

[Cancer Cell @Cancer_Cell]

Our June issue is fresh off the press. Go read it now: https://t.co/BP0Mburcx2